Vimarsana
Biggest News Aggregation in the World

Page 2 - Gil Efron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gil Efron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gil Efron Today - Breaking & Trending Today

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors - Vimarsana News

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief...

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial - Vimarsana News

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 --  Purple Biotech Ltd. , a clinical-stage company...

Purple Biotech Reports Third Quarter 2023 Financial - Vimarsana News

Purple Biotech Reports Third Quarter 2023 Financial

Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24...

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action - Vimarsana News

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported new biomarker data for its lead oncology drug, CM24, a first-in-class anti-CEACAM1 monoclonal antibody. Data were presented at the American Association for Cancer Research (AACR) Special Co

Source: yahoo.com
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer - Vimarsana News

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab;  2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...